Big Pharma Pushes for New Antibiotic Funds to Fight Superbugs

  • Group of 83 companies asks governments to join global action
  • Antibiotic development hampered by lower pricing for new drugs

Pharmaceutical giants including GlaxoSmithKline Plc and Merck & Co. are joining a large group of health-care companies to accelerate the development of drugs and diagnostics for “superbug” infections, trying to come up with a viable commercial model as an increasing number of bacteria become resistant to common antibiotics.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.